Costos directos de la atención del cáncer de mama en Colombia

Gamboa, Óscar; Buitrago, Lina; Lozano, Teõfilo; Dieleman, Sabrina; Gamboa, Carlos; Guzmán, Érika León; Gil, M. Viana; Barrientos-Fuentes, Juan Carlos

doi:10.1016/j.rccan.2016.02.003

Cited by 15 publications

(18 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 For 2016 in Colombia, metastatic cancer was associated with a total cost of US $53,000 per patient during a 5-year follow-up period, while regional breast cancer reached a cost close to US $25,000, without taking relapses into account. 4 In addition, costs of chemotherapy were estimated to represent 77-84% of the total cost according to the disease stage, which is consistent with other reports worldwide in which these costs were estimated to be 42-87% of the total costs. 6,7 Breast cancer with amplification of the ERBB2 gene and/or overexpression of transmembrane proteins of the HER2 family of epidermal growth receptors has been identified in 10-34% of the invasive breast cancers, 8 and it is considered to be associated with a poor prognosis due to its high proliferative and histological characteristics.…”

Section: Introductionsupporting

confidence: 88%

“…The active principle of medicines was filtered obtaining their cost. 43 Costs of medical consultations; diagnostic tests and follow-up (clinical laboratory, imaging, and tissue biopsy); extension studies; surgical treatment; adjuvant chemotherapy; radiotherapy; and rehabilitation were obtained from the study of Gamboa (2016). Since this study estimated costs for the treatment of cancer in Colombia at all stages, we used the annual average cost for stages III and IV (according to the American Joint Committee on Cancer Staging System for Breast Cancer).…”

Section: Evaluation Of Costsmentioning

confidence: 99%

“…Since this study estimated costs for the treatment of cancer in Colombia at all stages, we used the annual average cost for stages III and IV (according to the American Joint Committee on Cancer Staging System for Breast Cancer). 4 All costs related to diagnostic tests and procedures common to both interventions selected for this study were excluded, as well as costs associated with hormone therapy, since the target population is not eligible for this type of treatment.…”

Section: Evaluation Of Costsmentioning

confidence: 99%

“…3 However, overall survival can decrease due to delay in initiating treatment, simultaneously increasing health-care costs associated with advanced clinical stages. 4 Health-care costs for breast cancer are high. It has been estimated that by 2035, the United States will spend between 3.6 and 7.6 trillion dollars on patients with breast cancer.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

<p>Analysis of the Cost-Effectiveness of Liquid Biopsy to Determine Treatment Change in Patients with Her2-Positive Advanced Breast Cancer in Colombia</p>

Calderón

Pedraza

Urrego

et al. 2020

CEOR

View full text Add to dashboard Cite

Background: Breast cancer is highly prevalent worldwide and leads to high health-care costs. HER2-positive subtype represents 30% of all breast cancers and is associated with a poor prognosis. Patients treated with anti-HER2 therapies frequently develop resistance and require pharmacological treatment change. Liquid biopsy is a minimally invasive and an easily accessible technique, with high sensitivity and specificity, to detect molecular treatment resistance even before the onset of clinical manifestations and can thus be used to reduce unnecessary anti-HER2 treatment costs. Objective: To evaluate the cost-effectiveness of using liquid biopsy (ctDNA detection) to determine treatment change in women with HER2-positive advanced breast cancer in Colombia. Methodology: We performed an economic evaluation using decision tree modeling and deterministic analyses based on literature search for first and second lines of treatment (trastuzumab, pertuzumab, docetaxel, and TDM1); resistance; outcomes; and sensitivity and specificity of tests detecting molecular resistance. The effectiveness was measured using quality-adjusted life year (QALY) score, and costs were obtained from databases with national validity, suppliers, the Colombian Drug Price Information System (SISMED), and local studies. Results: The use of liquid biopsy (ctDNA detection) with conventional treatment was more expensive and less effective than conventional treatment without liquid biopsy (US $177,985.35 and 0.533889206 QALY, respectively). The incremental cost with liquid biopsy was US $7,333.17 and the incremental effectiveness was 0.00042256 QALY relative to the conventional method. Conclusion: Including liquid biopsy in the treatment of HER2-positive advanced breast cancer was considered currently inapplicable in Colombia because it was not cost effective. Our results open a window of opportunity to improve the development and implementation of ctDNA testing in Colombia, potentially reducing current costs. More evidence is required on the utility of this test, depending on the financial capacity of Colombia and other countries.

show abstract

Section: Introductionsupporting

confidence: 88%

Section: Evaluation Of Costsmentioning

confidence: 99%

Section: Evaluation Of Costsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

<p>Analysis of the Cost-Effectiveness of Liquid Biopsy to Determine Treatment Change in Patients with Her2-Positive Advanced Breast Cancer in Colombia</p>

Calderón

Pedraza

Urrego

et al. 2020

CEOR

View full text Add to dashboard Cite

show abstract

“…Esta situación genera un grave impacto social y económico. Estos datos resaltan la importancia de diagnosticar la enfermedad en estadios tempranos, donde la prevención secundaria juega un rol importante, no solo para proporcionar mejor esperanza de vida sino para reducir la necesidad de más cantidad de tratamientos, el riesgo de dolor por complicaciones de la enfermedad (que impacta sobre la calidad de vida) y los costos económicos 27 .…”

Section: Declaración De Conflicto De Interesesunclassified

Calidad de vida en pacientes con linfedema por cáncer de seno en la ciudad de Medellín

Legarda

Muñetón

Arenas

2020

MedUPB

View full text Add to dashboard Cite

Objetivo: Evaluar la calidad de vida en un grupo de pacientes con linfedema por cáncer de seno en la ciudad de Medellín. Metodología: Se realizó un estudio cuantitativo de tipo descriptivo correlacional, en el que se analizó la relación de la calidad de vida con la sintomatología, tratamientos médicos recibidos y perímetros del brazo en 11 mujeres con linfedema. Se valoró el dolor, perímetros de ambos brazos y se utilizó el cuestionario de calidad de vida FACT B+4. Resultados: A partir de las correlaciones de Spearman se identificó que, para la calidad de vida y los perímetros del brazo afectado, hubo una correlación inversa y no significativa, lo que indica que no existe una percepción negativa frente a la calidad de vida pese al linfedema. Hubo una correlación inversa y significativa entre el número de tratamientos y la calidad de vida (a más número de tratamientos recibidos, menor calidad de vida según la percepción de las participantes). Así mismo, la percepción de calidad de vida se correlacionó de modo inverso con el dolor. Conclusión: La calidad de vida se ve influenciada por la cantidad de tratamientos oncológicos recibidos, dichos tratamientos tienen efectos colaterales e impactan el bienestar. El dolor es una complicación que influye negativamente en la calidad de vida, más aún si se trata no se trata oportunamente.

show abstract

Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Costos directos de la atención del cáncer de mama en Colombia

Cited by 15 publications

References 6 publications

<p>Analysis of the Cost-Effectiveness of Liquid Biopsy to Determine Treatment Change in Patients with Her2-Positive Advanced Breast Cancer in Colombia</p>

<p>Analysis of the Cost-Effectiveness of Liquid Biopsy to Determine Treatment Change in Patients with Her2-Positive Advanced Breast Cancer in Colombia</p>

Calidad de vida en pacientes con linfedema por cáncer de seno en la ciudad de Medellín

Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review

Contact Info

Product

Resources

About